Preferred Label : Ribociclib/Letrozole;
NCIt synonyms : Ribociclib Letrozole; Ribociclib and Letrozole Co-pack; Ribociclib Plus Letrozole; Ribociclib-Letrozole Regimen; Ribociclib-Letrozole; Kisqali Femara Co-pack; Ribociclib Succinate/Letrozole;
NCIt definition : An orally available co-packaged agent combination of the succinate salt form of ribociclib,
a cyclin-dependent kinase (CDK) inhibitor targeting cyclin D1/CDK4 and cyclin D3/CDK6,
and letrozole, a nonsteroidal inhibitor of estrogen synthesis, with antineoplastic
activity. Upon oral administration, ribociclib specifically inhibits CDK4 and CDK6,
thereby inhibiting retinoblastoma (Rb) phosphorylation. Inhibition of Rb phosphorylation
prevents CDK-mediated G1-S phase transition, thereby arresting the cell cycle in the
G1 phase, suppressing DNA synthesis and inhibiting cancer cell growth. Letrozole selectively
and reversibly inhibits aromatase, which may result in growth inhibition of estrogen-dependent
cancer cells.;
Drug name : Kisqali/Femara; Kisqali and Femara Co-pack;
NCI Metathesaurus CUI : CL759918;
Origin ID : C154675;
UMLS CUI : C4477758;
Semantic type(s)
- concept_is_in_subset
- has_target
